SCHEMBL1645844

SCHEMBL1645844

Cc1cc(C)nc(N2CCN(c3cccc(N)c3)CC2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
GFER P55789 1/20 0.56
ADRA2C P18825 1/20 0.55
KDM4E B2RXH2 4/20 0.49
LMNA P02545 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KCNH2 Q12809 1/20 0.48
IRAK4 Q9NWZ3 1/20 0.47
DHFR P00374 2/20 0.45
ALOX15 P16050 2/20 0.44
ALDH1A1 P00352 2/20 0.44
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.44
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
CHRM1 P11229 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL943023 0.85 MAPT (0.55) MAPTGFERADRA2CKDM4ELMNA
SCHEMBL942660 0.81 GAA (0.55) MAPTGFERKDM4ELMNATSHR
SCHEMBL942722 0.81 MAPT (0.51) MAPTGFERADRA2CKDM4ELMNA
SCHEMBL1127038 0.79 PHGDH (0.47) MAPTGFERKDM4ELMNATSHR
SCHEMBL1019837 0.79 MAPT (0.46) MAPTGFERKDM4ELMNATSHR
SCHEMBL943720 0.78 MAPT (0.56) MAPTGFERKDM4ELMNAIRAK4
SCHEMBL943333 0.77 MAPT (0.56) MAPTGFERKDM4EALDH1A1POLB
SCHEMBL6942579 0.77 ADRA2C (0.80) MAPTGFERADRA2CKDM4ELMNA
SCHEMBL942659 0.76 MAPT (0.40) MAPTGFERKDM4ELMNATSHR
Hydrochloric Acid SCHEMBL7077636 0.75 ADRA2C (0.77) MAPTGFERADRA2CKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097413-B1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2013-12-25 EP disclosed
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed
EP-2303329-A1 ANTIFUNGAL COMBINATION THERAPY F2G Limited (GB) 2011-04-06 EP disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 WO disclosed
EP-2097413-A1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G Limited (GB) 2009-09-09 EP disclosed
WO-2008062182-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 MAPT 1771/4885GFER 3245/4885ADRA2C 609/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 MAPT 2950/4885GFER 1317/4885ADRA2C 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.